Publicacións (43) Publicacións de Olalla Maroñas Amigo

filter_list

2025

  1. A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines

    International Journal of Molecular Sciences, Vol. 26, Núm. 17

  2. Balance of care activity after EMA recommendation for DPYD gene testing in Galicia

    Frontiers in Pharmacology, Vol. 16

  3. Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study

    Pharmaceuticals, Vol. 18, Núm. 4

  4. Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies

    Journal of Psychiatric Research, Vol. 190, pp. 512-521

  5. Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations

    Scientific Reports, Vol. 15, Núm. 1

  6. Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients

    Biomedicines, Vol. 13, Núm. 3

  7. The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review

    Pharmaceuticals, Vol. 18, Núm. 5

  8. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

    European Psychiatry, Vol. 68, Núm. 1

2024

  1. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition

    Schizophrenia Research, Vol. 268, pp. 302-307

  2. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine

    Pharmacological Research, Vol. 200

  3. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies

    Schizophrenia Research, Vol. 268, pp. 293-301

  4. Farmacogenética

    Medicina interna (Elsevier España), pp. 1284-1291

  5. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  6. Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives

    Drug Metabolism and Personalized Therapy, Vol. 39, Núm. 4, pp. 183-199

  7. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case report

    Frontiers in Pharmacology, Vol. 14

  2. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

    Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34

2021

  1. Genetic diversity of drug-related genes in native americans of the brazilian amazon

    Pharmacogenomics and Personalized Medicine, Vol. 14, pp. 117-133

  2. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7